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ABSTRACT
Objective: As per requisition of current regulatory requirements, simple, rapid and sensitive method by 33 factorial quality by design approach was 
established and validated for Ambroxol (AMB) by reversed-phase high-performance liquid chromatography (RP-HPLC).
Methods: A simple RP-HPLC method has been developed and validated with different parameters such as linearity, precision, repeatability, limit of 
detection (LOD), limit of quantitation (LOQ), accuracy as per International Conference for Harmonisation guidelines (Q2R1). Statistical data analysis 
was done for data obtained from different aliquots Runs on Agilent Tech. Gradient System with Auto injector, ultraviolet (UV) diode-array detection 
and Gradient Detector.
Results: Equipped with Reverse Phase (Agilent) C18 column (4.6 mm × 100 mm; 2.5 µm), a 20 µl injection loop and UV730D Absorbance detector at 
244 nm wave length and running chemstation 10.1 software and drugs along with degradants were separated via Methanol: (0.1% orthophosphoric 
acid) Water (75:25) of pH 3 as mobile phase setting flow rate 0.7 ml/min at ambient temperature the retention time of AMB were found to be 4.85 min. 
The industrialized method was found linear over the concentration range of 10–50 µg/ml for AMB while the LOD and LOQ of AMB was found to be 
0.5174–0.2739 µg/ml, analytical method that concluded.
Conclusion: There are no interfering peaks underperformed degradation conditions. Therefore, a sensitive, robust, accurate, and stability indicating 
method was developed with high degree of practical utility.
Keywords: Ambroxol, Quality by design, Reversed-phase high-performance liquid chromatography, Stability study, Method development, Validation.
INTRODUCTION
The concept of “quality by design” (QbD) was defined as an approach 
that covers a better scientific understanding of critical process and 
product qualities, designing controls and tests based on the scientific 
limits of understanding throughout the development phase and 
by the knowledge obtained during the life-cycle of the product to 
work on a continuous improvement environment. QbD describes 
a pharmaceutical development approach referring to formulation 
design and development and manufacturing processes to maintain 
the prescribed product quality. Guidelines and mathematical models 
are used to ensure the establishment and use of the knowledge on the 
subject in an independent and integrated way [1-3].
Ambroxol hydrochloride (HCL) [4,5] is a potent mucolytic and 
mucokinetic. Ambroxol (AMB) HCL is chemically Trans-4-([2-amino-3, 
5-dibromobenzyl] amino)-cyclohexanol HCL (Fig. 1). AMB is indicated 
as “secretolytic therapy in bronchopulmonary diseases associated with 
abnormal mucus secretion and impaired mucus transport. It promotes 
mucus clearance, facilitates expectoration, and eases productive cough, 
allowing patients to breathe freely and deeply.”
Moreover, the extensive literature inspection revealed that there is 
no reversed-phase high-performance liquid chromatography (RP-
HPLC) method obtainable for simultaneous estimation of AMB in the 
pharmaceutical dosage forms using experimental design approach 
QbD. A few analytical methods [6,7] have been reported in the literature 
for the determination of levofloxacin or AMB alone or combination with 
other drugs biological fluids, and pharmaceutical dosage forms. They 
include derivative spectrophotometric [8,9] methods and other methods 
such as HPLC with ultraviolet (UV) detection, high-performance thin-
layer chromatography [10,11], and liquid chromatography with tandem 
mass spectrometry were also reported for the determination of AMB 
from human body fluids and pharmaceutical dosage form.
Regulatory authorities such as Food and Drug Administration 
and International Conference for Harmonisation (ICH) 
guidelines [12-14] are promoting and requesting the application 
of experimental design approach to understand chromatographic 
selectivity and support better method control, including method 
transfer. This prompted the investigators to adopt the experimental 
design in HPLC, and many papers were published related to this 
work [15-18]. The main impartial of our work is to develop an 
improved RP-HPLC method suitable for the routine quality control 
of AMB in a pharmaceutical industry and provide information on the 
sensitivity of chromatographic factors and their interaction effects 
on the separation characteristics. In our studies, no method has been 
reported for simultaneous estimation of the AMB drugs by using QbD 
based 33 factorial designing.
METHODS
Chemicals and reagents
Reference standards of Naproxen HCL were obtained as gift sample from 
R.S.I.T.C Jalgaon, India. Pharmaceutical formulation was purchased after 
local market (Brand: Ambrolite tablet labeled claim AMB 30 mg tablets 
India Ltd. 100 tab). The HPLC grade solvents used were of E-Merck 
(India) Ltd., Mumbai. HPLC grade Methanol and Ortho Phosphoric Acid 
(Merck, Mumbai, India) were used in the analysis. HPLC grade water 
was prepared using Millipore purification system.
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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Instruments
The analysis of the drug was conceded out on Agilent Tech. Gradient 
System with Autoinjector, UV diode-array detection and Gradient 
Detector. Equipped with Reverse Phase (Agilent) C18 column (4.6 mm 
× 100 mm; 2.5 µm), a 20 µl injection loop and UV730D Absorbance 
detector and running chemstation 10.1 software.
RP-HPLC optimised chromatographic condition using QbD
Column C18 (100 mm × 4.6 mm); particle size packing 5 µm; detection 
wavelength 244 nm; flow rate 0.7 ml/min; temperature 26°C ambient; 
sample size 20 µl; mobile phase methanol: Water (Orthophosphoric 
acid 0.1% PH 3) (75:25); run time 15 min. The retention time (RT) for 
AMB was found at 3.822 min (Fig. 2).
Preparation of std. AMB solution: (Stock I)
An accurately weighed quantity, 10 mg of AMB was dissolved in 
methanol in a 10 ml volumetric flask and volume made up to 10.0 ml to 
produce a solution of 1000 µg/ml. From the freshly prepared standard 
stock solution (1000 µg/ml), 0.1ml stock solution was pipetted out 
in 10 ml of volumetric flask, and volume was made up to 10 ml with 
mobile phase to get final concentration of 10 µg/ml.
Preparation of std. AMB solution: (Stock III)
From the freshly prepared standard stock solution (1000 µg/ml), 0.1 ml 
stock solution was pipette out in 10 ml of volumetric flask, and volume 
was made up to 10 ml with mobile phase to get final concentration 
10 µg/ml.
QbD approach to analysis
The application of QbD in HPLC method growth commences with 
establishing analytical objectives based on sound science to ensure 
consistent method presentation characteristics are achieved. The use 
of QbD for an analytical way begins with defining the target analytical 
profile in which the pre-defined objectives for method performance 
must be appropriately validated and documented.
Thus the objective of this work was to perform experimental design 
by using Design Expert Software leading to develop simple, rapid, and 
sensitive method by QbD approach and validated as per ICH Guidelines 
(Q2R1) for Naproxen and Pantoprazole and its stability indicating 
method by RP-HPLC. Further statistical data analysis to be done along 




A calibration curve was constructed succeeding replicate (n=6) analysis 
of five standards of 10, 20, 30, 40, and 50 µg/ml of AMB. The peak 
height ratio of drugs was calculated and plotted area under the curve 
(AUC) versus concentration after which least squares linear regression 
analysis of data was undertaken to establish the equation for the best fit 
line and the correlation coefficient (R2) to authorize linearity. Samples 
were injected and peaks were recorded at 244 nm and the graph 
plotted as concentration of drug versus peak area as shown in (Table 1 
and Fig. 3).
Precision
Intra-day (repeatability) precision was established following analysis 
of replicate samples (n=6) at three concentrations indicative of low, 
medium, and tall levels within the linear range viz., 20, 30 and 40 µg/
ml of AMB. Analysis was performed over a small period of time on 
the same day. Inter-day precision or reproducibility was assessed at 
low, medium, and high concentration on three consecutive days and 
the percent relative standard deviation (% RSD) was used to assess 
intra- and inter-day precision. An upper limit of 2% was used to confirm 
precision in our laboratory. Precision of an analytical method is usually 
expressed as standard deviation or RSD (Table 2).
Accuracy
Recovery studies were performed to validate the accuracy of developed 
method. To pre-analyzed tablet solution, a definite concentration 
of standard drug (80%, 100%, and 120%) was added and then its 
recovery was analyzed. Statistical validation of recovery studies shown 
in (Table 3).
Specificity
The specificity of an analytical method is defined as the ability of a 
method to ensure that the peak(s) of interest elute as distinct responses 
in the presence of excipients, impurities or degradation compounds.
Robustness
To evaluate robustness few parameters were deliberately varied. The 
parameters include variation of flow rate, percentage of methanol as 
described in (Table 4).
Study of system suitability parameters
The system suitability is used to verify, whether the resolution and 
reproducibility of the chromatographic system are adequate for 
analysis to be done. The test was performed by collecting data from five 
replicate injections of standard solution as shown in (Table 5).
Analytical method for tablet formulation
Weigh 20 AMB tablets and calculated the average weight, accurately 
weigh and transfer the sample equivalent to 21 mg AMB into 10 ml 
volumetric flask. Add about 10ml MEOH of diluent and sonicate to 
dissolve it completely and make volume up to the mark with diluent. 
Mix well and filter through 0.45 µm filter. Further pipette 0.1 ml of the 
above stock solution into a 10 ml volumetric flask and dilute up to the 
Fig. 1: Structure of ambroxol
Fig. 2: Chromatogram of standard ambroxol at 244 nm Fig. 3: Calibration curve of ambroxol
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mark with diluents (10 µg/ml). The simple chromatogram of test AMB 
Shown in (Fig. 4) the amounts of AMB per tablet were calculated by 
extrapolating the value of area from the calibration curve. Analysis 
procedure was repeated five times with tablet formulation. Tablet Assay 
for %Label claim for % RSD Calculated, Result was shown in (Table 6).
Forced degradation studies
Forced degradation study was performed to evaluate the stability of 
the developed method using the stress conditions such as exposure of 
sample solution to acid, base, Hydrogen peroxides (H2O2), and Neutral. 
Investigation was done for the degradation products in different 
conditions and are shown in (Table 7).
Table 1: Linearity study AMB
Method Conc. µg/ml Peak area (µV.s) Average peak area (µV.s) S.D. of Peak Area % RSD of Peak Area
1 2
UHPLC Method 1 10 88.711 88.5226 0.2664 0.3010
2 20 173.5036 173.5963 0.1310 0.0755
3 30 260.3951 260.6494 0.3596 0.1380
4 40 350.7162 350.5986 0.1664 0.0475
5 50 438.3293 438.1269 0.2863 0.0653
Equation y=8.762×–0.564
R2 0.999
AMB: Ambroxol, UHPLC: Ultra-high performance liquid-chromatography
Table 2: Intraday and Inter day Precision studies on RP-HPLC method for AMB
Drug Method Conc. (µg/ml) Interday Precision Intraday Precision
Mean±SD %Amt Found Mean±SD %Amt Found
AMB HPLC 10 462.24±1.43 101.76 460.97±0.78 101.50
30 1431.44±1.62 99.70 1430.78±0.67 99.65
50 2427.94±1.48 100.44 2429.47±1.56 100.46
AMB: Ambroxol, HPLC: High performance liquid-chromatography, *Mean of each 3 reading for reversed-phase high-performance liquid chromatography method
Table 3: Results of recovery studies AMB for RP-HPLC method
Level (%) Amt. taken (μg/ml) Amt. Added (μg/ml) Absorbance Mean*±S.D. Amt. recovered Mean *±S.D. %recovery Mean*±S.D.
80 10 8 18.00±0.065 8.00±0.067 100.04±0.82
100 10 10 20.01±0.043 20.58±0.043 100.19±0.42
120 10 12 22.00±0.022 20.58±0.23 100.01±0.18
*mean of each 3 reading, AMB: Ambroxol, RP-HPLC: Reversed-phase high-performance liquid chromatography
Table 4: Robustness evaluation of the HPLC method for AMB
Parameters Conc. (µg/ml) Amt. of detected (mean±SD) %RSD
Chromatogram of flow change 0.6 ml 50 512.18±0.73 0.14
Chromatogram of flow change 0.8 ml 50 383.69±2.36 0.62
Chrom. of comp change wavelength change 243 nm 50 418.1±0.66 0.16
Chrom. of comp change wavelength change 245 nm 50 466.68±1.20 0.26
Chrom. of mobile phase change 74+26 ml 50 439.4±1.20 0.27
Chrom. of mobile phase change 76+24 ml 50 438.83±0.66 0.16
AMB: Ambroxol, HPLC: High-performance liquid chromatography, RSD: Relative standard deviation
Table 5: Repeatability studies on RP-HPLC method for AMB
Conc. of AMB 
 (mg/ml)







Mean 350.4191 40.0574 100.1435
SD 0.7508
%RSD 0.2143
AMB: Ambroxol, RP-HPLC: Reversed-phase high-performance liquid 
chromatography, RSD: Relative standard deviation
Table 6: Analysis of marketed formulation
Method Amt. Found % Label Claim SD % RSD
UHPLC 50.14 99.89 0.06 0.06
50.14 99.33 0.03 0.03
UHPLC: Ultra-high performance liquid-chromatography, RSD: Relative standard 
deviation
Fig. 4: Chromatogram for marketed formulation
47
Asian J Pharm Clin Res, Vol 14, Issue 12, 2021, 44-49
 Ahmad et al.
Fig. 10: Heat degradation
Fig. 5: Normal plot of residuals for retention time and plot of predicted versus actual data for retention time of cp
Fig. 7: Acidic degradation
Fig. 6: Contour plot for flow rate, mobile phase composition and wave length
Fig. 9: Peroxide degradation
Fig. 8: Alkaline degradation
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Procedure for AMB degradation
Acid hydrolysis
The acid hydrolysis performed using 0.1N HCl at 70°C for 1st h for AMB 
to indicate degradation. The major degradation product for AMB was 
observed at relative RT (RRT) for 1st h.
Alkaline hydrolysis
The alkaline hydrolysis condition was performed using 0.1N NaOH at 
70°C for 1st h for AMB. The major degradation product for AMB was 
observed at RRT for 1st h.
Oxidation
In the oxidation condition with 3% H2O2 for 1st h AMB show oxidative 
stress degradation peak in the chromatogram.
Neutral
There was no major degradation observed for AMB and hence they 
were not sensitive to light at 70°C for 1st h.
RESULTS AND DISCUSSION
Such analytical methods are, in fact, an indicator of a quality product 
and the robustness of that product for the duration on the lifecycle of 
that product. The main goal of any HPLC method is to separate and 
quantitate analyte(s) of interest from any impurity and/or excipients. 
Initially, it is important to establish the critical quality attributes 
of a system that may impact the quality of the analytical method. 
Development of Analytical RP-HPLC Method with Design Space 
and Control Strategy determination by optimization study all the 
computations for the current optimization study and statistical analysis 
were performed using Design Expert® software (Design Expert trial 
version). State-Ease Inc., Minneapolis, MN, USA).
Application of design of experiments (DOE-1) for method 
optimization DOE-1
Thus, 3 randomized response surface designs with a full fraction 
design were used with 17 trial runs to study the impact of three 
factors on the three key response variables. In this design three 
factors were evaluated, each at three levels and experimental trials 
were performed at all three possible combinations. The mobile 
phase composition (χ1), Wavelength (χ2), and flow rate (χ3) were 
selected as independent variables and RT and Resolution were 
selected as dependent variables. The resulting data were fitted into 
Design Expert 10 Software and analyzed statistically using analysis 
of variance (ANOVA) and F-Test (Fig. 5) indicates the normal plot 
of residuals for RT with other chromatographic parameters. The 
data were also subjected to 3-D response surface methodology 
to determine the influence of flow rate, Wavelength, and mobile 
phase composition on dependent variables as shown in (Fig. 6). 
The probable trial runs using 33 full fraction designs are as shown 
in (Table 4). Further ANOVA and F-test with variables are shown in 
(Tables 8-11). Moreover degradation peaks of API were shown in 
(Figs. 7-10) from acidic, alkaline, peroxide, and Heat.
Table 9: ANOVA for reduced quadratic model (response 1: RT)
Source Sum of Squares Df Mean Square F-value p-value
Model 20.76 5 4.15 700.57 <0.0001 significant
A-Flow rate 6.20 1 6.20 1046.53 <0.0001
B-Methanol 14.11 1 14.11 2380.50 <0.0001
AB 0.1600 1 0.1600 27.00 0.0138
A² 0.0672 1 0.0672 11.34 0.0435
B² 0.2222 1 0.2222 37.50 0.0088
Residual 0.0178 3 0.0059
ANOVA: Analysis of variance, RT: Retention time
Table 7: Forced degradation
Sample exposure condition Total number of products with their Rt AMB
Degradation remained (20 µg/ml) Recovery (%)
Acidic, 0.1N, 1 h 3 (1.65, 2.91, 3.62) 15.594 77.97
Basic, 0.1N, 1 h 4 (1.58, 1.68, 1.95, 2.61) 12.293 61.465
Per oxide, 3%, 1 h 6 (1.57, 1.87, 2.50, 2.67, 2.92, 3.64) 7.134 35.67
Heat, 70°C, 1 h 3 (1.88, 2.92, 3.65) 18.20 91.05
AMB: Ambroxol, RT: Retention time
Table 8: Probable trial runs using full fraction designs








ml/min % Nm min AUC Number
9 1 0.8 80 230 4.8 141.02 11675
6 2 0.8 75 231 5.9 143.55 10892
8 3 0.7 80 232 5.5 160.76 11693
5 4 0.7 75 231 6.7 163.82 12789
3 5 0.8 70 230 7.5 144.17 11458
2 6 0.7 70 232 8.5 163.9 9810
4 7 0.6 75 232 7.8 191.94 11373
1 8 0.6 70 229.3 10 191.78 10645
7 9 0.6 80 230 6.5 189.27 9777
RT: Retention time, AUC: Area under the curve
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CONCLUSION
A simple, rapid, reliable, robust, and optimized reversed phase high-
performance liquid chromatographic method for estimation of Naproxen 
and Pantoprazole was successfully developed and validated as per ICH 
guidelines. Percentage of mobile phase, flow rate, and wavelength was 
optimized by using QbD approach i.e. 33 factorial design. There are no 
interfering peaks underperformed degradation conditions. Therefore, a 
sensitive, accurate, and stability-indicating method was developed with 
high degree of practical utility.
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